Relapsing-Remitting Multiple Sclerosis (MS) Market Size, Share, Growth, and Industry Analysis, By Types (Immunomodulating Drugs, Nrf2 Activators, Interferons, Others, ), By Applications (Hospitals, Clinics, Others, ) , and Regional Insights and Forecast to 2035

Relapsing-Remitting Multiple Sclerosis (MS) Market Size

Global Relapsing-Remitting Multiple Sclerosis (MS) Market size was valued at USD 5.57 billion in 2025 and is projected to reach USD 5.99 billion in 2026 and USD 6.44 billion in 2027. The market is further expected to reach USD 11.45 billion by 2035, expanding at a CAGR of 7.47% during the forecast period from 2026 to 2035. More than 68% of patients prefer long-term disease-modifying therapies, while over 52% of healthcare providers are increasing the use of advanced neurological monitoring systems. Around 44% of treatment demand comes from biologic therapies due to better relapse management results.

The US Relapsing-Remitting Multiple Sclerosis (MS) Market is witnessing strong growth because of increasing neurological disorder awareness and rising treatment accessibility. More than 63% of patients in the United States receive continuous disease management therapies through hospitals and specialty clinics. Around 49% of healthcare institutions are expanding digital neurology support services for patient monitoring and rehabilitation. Approximately 41% of pharmaceutical research activities related to relapsing-remitting multiple sclerosis are concentrated in the US market. Increasing use of biologics, oral medications, and personalized therapies is also supporting long-term market expansion across the country.

Key Findings

• Market Size: Global Relapsing-Remitting Multiple Sclerosis (MS) Market reached USD 5.57 billion in 2025, USD 5.99 billion in 2026, and USD 11.45 billion by 2035 at 7.47% growth.
• Growth Drivers: More than 68% patients demand long-term therapies, while 52% healthcare providers expand neurological treatment programs and advanced monitoring systems.
• Trends: Around 44% biologic therapy adoption and 36% digital healthcare integration are improving treatment management and patient monitoring activities globally.
• Key Players: Biogen, Novartis AG, Merck KGaA, Sanofi Genzyme, Teva Pharmaceutical Industries Ltd & more.
• Regional Insights: North America holds 39% market share, Europe 30%, Asia-Pacific 22%, and Middle East & Africa 9% with growing neurological treatment demand.
• Challenges: Nearly 43% patients face therapy side effects, while 37% experience treatment adherence issues and 31% report limited specialist accessibility.
• Industry Impact: More than 48% healthcare facilities are improving neurological diagnosis systems, while 34% increase investments in digital patient management platforms.
• Recent Developments: Around 29% companies expanded biologic therapy research, while 24% improved digital neurological monitoring and rehabilitation support programs globally.

The Relapsing-Remitting Multiple Sclerosis (MS) Market is highly focused on long-term patient management and neurological rehabilitation services. More than 58% of patients require continuous monitoring and therapy adjustments to control relapse frequency and mobility problems. Around 46% of healthcare providers are adopting personalized medicine approaches to improve treatment effectiveness and reduce immune-related complications. Digital health platforms are being used by nearly 33% of treatment centers for remote patient monitoring and therapy tracking. Increasing use of oral medications, biologics, and rehabilitation support programs is helping improve patient quality of life and long-term neurological care outcomes globally.

Relapsing-Remitting Multiple Sclerosis (MS) Market Trends

The Relapsing-Remitting Multiple Sclerosis (MS) Market is showing strong growth due to the rising number of neurological disorder cases and growing awareness about early diagnosis. More than 80% of multiple sclerosis patients are diagnosed with relapsing-remitting multiple sclerosis during the initial stage, making it the most common form of the disease. Around 65% of patients prefer disease-modifying therapies because these treatments help reduce relapse frequency and improve mobility conditions. Over 58% of hospitals and neurology centers have increased the use of advanced imaging technologies for faster diagnosis of relapsing-remitting multiple sclerosis. Oral therapies account for nearly 45% of treatment demand due to easier administration and higher patient comfort.

The use of biologics and monoclonal antibodies has increased by more than 40% because of their effectiveness in reducing nerve damage progression. Approximately 52% of healthcare providers are focusing on personalized treatment plans for relapsing-remitting multiple sclerosis patients to improve long-term outcomes. North America contributes more than 38% of global treatment demand due to advanced healthcare infrastructure and high patient awareness levels. Europe represents nearly 30% of the relapsing-remitting multiple sclerosis market because of strong neurological research programs and supportive reimbursement policies. Asia-Pacific is witnessing fast adoption, with treatment awareness increasing by over 35% among urban populations. More than 48% of pharmaceutical companies are investing in pipeline drugs and clinical trials targeting relapsing-remitting multiple sclerosis therapies. Digital monitoring tools and telemedicine support have grown by around 33%, helping patients manage symptoms more effectively and increasing treatment adherence across healthcare systems.

Relapsing-Remitting Multiple Sclerosis (MS) Market Dynamics

OPPORTUNITY

"Expansion of Personalized Neurology Treatments"

The growing focus on personalized medicine is creating strong opportunities in the Relapsing-Remitting Multiple Sclerosis (MS) Market. More than 54% of neurologists are adopting customized treatment approaches based on patient symptoms and disease progression levels. Nearly 47% of patients respond better to targeted biologic therapies compared to traditional medications. Around 42% of healthcare institutions are increasing investments in genetic testing and biomarker analysis for neurological disorders. Digital health platforms used for multiple sclerosis monitoring have increased by over 36%, helping improve patient engagement and treatment tracking. In addition, nearly 50% of pharmaceutical companies are expanding research activities related to immune-based therapies for relapsing-remitting multiple sclerosis management.

DRIVERS

"Rising Demand for Advanced Multiple Sclerosis Therapies"

The increasing demand for effective neurological treatments is a major driver for the Relapsing-Remitting Multiple Sclerosis (MS) Market. More than 68% of patients seek long-term therapies that reduce relapse frequency and improve physical movement. Approximately 49% of treatment centers have increased the use of oral medications due to higher patient convenience and compliance levels. Monoclonal antibody therapies have shown adoption growth of over 41% because of improved clinical performance. Around 57% of healthcare professionals prefer early-stage intervention to reduce nerve damage risks in relapsing-remitting multiple sclerosis patients. Furthermore, nearly 39% of patients are using digital support programs and rehabilitation services to manage symptoms more efficiently and improve quality of life.

RESTRAINTS

"High Treatment Complexity and Side Effects"

The Relapsing-Remitting Multiple Sclerosis (MS) Market faces restraints due to treatment-related complications and therapy side effects. More than 43% of patients report fatigue, infections, or immune-related complications during long-term treatment usage. Around 37% of individuals discontinue therapies because of poor tolerance levels and complex dosing schedules. Nearly 40% of rural healthcare facilities lack advanced neurology specialists required for proper disease management. Limited awareness among approximately 35% of patients delays early diagnosis and treatment initiation. In addition, over 32% of healthcare providers face challenges in maintaining consistent patient monitoring, especially for progressive neurological symptoms associated with relapsing-remitting multiple sclerosis.

CHALLENGE

"Rising Costs and Limited Access to Specialty Care"

One of the biggest challenges in the Relapsing-Remitting Multiple Sclerosis (MS) Market is limited access to specialized neurological care and advanced therapies. More than 46% of patients in developing regions experience delays in receiving proper treatment due to low specialist availability. Around 38% of healthcare systems face difficulties in maintaining continuous access to innovative therapies and monitoring services. Nearly 44% of patients require long-term rehabilitation and support programs, increasing overall disease management burden. Telemedicine adoption has increased by over 30%, but digital healthcare gaps still affect treatment continuity in remote areas. Additionally, approximately 34% of patients struggle with therapy adherence because of frequent hospital visits and ongoing clinical monitoring requirements.

Segmentation Analysis

The Relapsing-Remitting Multiple Sclerosis (MS) Market is segmented by type and application, with growing demand for advanced therapies and long-term patient care solutions. Global Relapsing-Remitting Multiple Sclerosis (MS) Market size was USD 5.57 Billion in 2025 and is projected to touch USD 5.99 Billion in 2026 to USD 11.45 Billion by 2035, exhibiting a CAGR of 7.47 % during the forecast period [2025-2035]. Immunomodulating drugs account for nearly 34% of the total treatment demand because of their strong relapse control effectiveness. Interferons contribute around 28% share due to wide prescription use among early-stage patients. Nrf2 activators hold close to 21% market participation because they help reduce nerve inflammation and oxidative stress. Hospitals represent more than 48% of application demand as patients require continuous neurological monitoring and infusion support. Clinics account for approximately 33% share due to increasing outpatient treatment programs and follow-up services. The growing use of digital healthcare platforms and personalized medicine is also supporting segmentation growth across different treatment categories and healthcare facilities.

By Type

Immunomodulating Drugs

Immunomodulating drugs remain one of the most preferred treatment categories in the Relapsing-Remitting Multiple Sclerosis (MS) Market because these therapies help reduce immune system attacks on nerve cells. More than 60% of neurologists recommend immunomodulating drugs during early-stage diagnosis to lower relapse frequency and improve patient mobility. Around 55% of patients using these therapies report better symptom management and reduced inflammatory activity. Increasing use of oral formulations and long-term disease management programs is also supporting segment growth across developed and emerging healthcare markets.

Immunomodulating Drugs Market Size was valued at USD 1.89 Billion in 2025 with nearly 34% market share and is expected to grow at a CAGR of 7.8% during the forecast period due to rising treatment adoption, better therapy effectiveness, and increasing awareness regarding early neurological care.

Nrf2 Activators

Nrf2 activators are gaining strong attention in the Relapsing-Remitting Multiple Sclerosis (MS) Market because they help reduce oxidative stress and nerve inflammation. Nearly 46% of specialists prefer Nrf2 activators for patients experiencing frequent relapses and fatigue-related complications. More than 40% of patients show improved daily activity levels after long-term use of these therapies. The segment is also benefiting from growing research activities focused on neuroprotection and immune regulation. Increasing awareness regarding advanced oral therapies is further improving demand across healthcare systems.

Nrf2 Activators Market Size reached USD 1.17 Billion in 2025, accounting for nearly 21% market share and is projected to expand at a CAGR of 7.3% during the forecast period because of increasing preference for targeted neurological therapies and better patient compliance levels.

Interferons

Interferons continue to play an important role in the Relapsing-Remitting Multiple Sclerosis (MS) Market due to their long-standing clinical use and strong physician trust. Approximately 58% of healthcare providers prescribe interferons to newly diagnosed patients because these drugs help reduce relapse severity and disease progression risks. Nearly 50% of treatment centers continue using injectable interferon therapies for long-term neurological care. Improved patient monitoring programs and better awareness regarding early treatment benefits are also increasing the use of interferons across several healthcare institutions.

Interferons Market Size stood at USD 1.56 Billion in 2025 with around 28% market share and is estimated to grow at a CAGR of 7.1% during the forecast period driven by continuous clinical usage and increasing diagnosis rates of relapsing-remitting multiple sclerosis.

Others

The others segment includes monoclonal antibodies and combination therapies used for advanced relapsing-remitting multiple sclerosis treatment. More than 37% of severe-condition patients are shifting toward advanced biologic therapies due to better symptom control and lower relapse recurrence. Around 44% of pharmaceutical companies are expanding research activities related to innovative neurological drugs. Increasing demand for personalized medicine and supportive rehabilitation therapies is helping this segment gain attention among specialists and healthcare providers globally.

Others Market Size accounted for USD 0.95 Billion in 2025, representing close to 17% market share and is expected to grow at a CAGR of 7.9% due to increasing biologic therapy adoption and rising investments in neurological drug development.

By Application

Hospitals

Hospitals remain the leading application area in the Relapsing-Remitting Multiple Sclerosis (MS) Market because patients require advanced neurological diagnosis, imaging support, and continuous monitoring services. Nearly 62% of severe relapsing-remitting multiple sclerosis patients prefer hospital-based treatment because of better emergency care and specialist access. Around 53% of infusion-based therapies are administered in hospitals due to safety monitoring requirements. The growing availability of advanced MRI technologies and rehabilitation programs is also strengthening hospital-based treatment demand worldwide.

Hospitals Market Size reached USD 2.67 Billion in 2025 with nearly 48% market share and is expected to expand at a CAGR of 7.6% during the forecast period because of rising patient admissions and increasing use of specialty neurological therapies.

Clinics

Clinics are witnessing stable growth in the Relapsing-Remitting Multiple Sclerosis (MS) Market due to increasing outpatient treatment demand and routine neurological follow-up services. Approximately 49% of patients prefer clinics for regular symptom monitoring and medication consultations because of shorter waiting times and easier appointment access. More than 38% of healthcare providers are expanding neurology-focused outpatient centers to improve treatment convenience. Clinics are also benefiting from rising telemedicine adoption and digital patient support programs.

Clinics Market Size accounted for USD 1.84 Billion in 2025, representing around 33% market share and is projected to grow at a CAGR of 7.4% during the forecast period driven by increasing outpatient treatment services and growing patient awareness.

Others

The others segment includes rehabilitation centers, homecare settings, and specialty neurological institutions involved in relapsing-remitting multiple sclerosis management. Nearly 35% of patients use rehabilitation services to improve mobility and reduce muscle weakness complications. Around 31% of long-term patients are adopting home-based care solutions supported by digital monitoring technologies. The increasing focus on patient comfort, therapy adherence, and remote healthcare support is helping this application segment expand steadily across multiple healthcare systems.

Others Market Size was valued at USD 1.06 Billion in 2025 with approximately 19% market share and is estimated to grow at a CAGR of 7.2% because of increasing rehabilitation demand and rising adoption of home-based neurological care solutions.

Relapsing-Remitting Multiple Sclerosis (MS) Market Regional Outlook

The regional outlook for the Relapsing-Remitting Multiple Sclerosis (MS) Market shows steady expansion across developed and emerging healthcare economies. Global Relapsing-Remitting Multiple Sclerosis (MS) Market size was USD 5.57 Billion in 2025 and is projected to touch USD 5.99 Billion in 2026 to USD 11.45 Billion by 2035, exhibiting a CAGR of 7.47 % during the forecast period [2026-2035]. North America holds around 39% market share due to high treatment awareness and advanced neurological care systems. Europe contributes nearly 30% share supported by strong reimbursement policies and clinical research activities. Asia-Pacific accounts for approximately 22% market participation because of increasing diagnosis rates and healthcare investments. Middle East & Africa represents close to 9% share with growing focus on neurological treatment access and specialty healthcare infrastructure development.

North America

North America remains a strong region in the Relapsing-Remitting Multiple Sclerosis (MS) Market due to high awareness levels, advanced healthcare systems, and strong access to disease-modifying therapies. More than 68% of diagnosed patients in the region receive continuous neurological treatment and monitoring support. Around 57% of hospitals use advanced MRI imaging technologies for faster multiple sclerosis diagnosis. Nearly 49% of pharmaceutical clinical trials related to neurological disorders are conducted across North America. Increasing adoption of biologics and personalized medicine is also improving treatment outcomes for relapsing-remitting multiple sclerosis patients. Digital healthcare usage has increased by over 36%, helping improve therapy adherence and patient engagement across treatment centers.

North America Market Size reached USD 2.34 Billion in 2026, accounting for nearly 39% market share due to strong healthcare spending, advanced treatment access, and rising neurological disease awareness across the region.

Europe

Europe continues to show stable growth in the Relapsing-Remitting Multiple Sclerosis (MS) Market because of strong public healthcare systems and growing neurological research programs. Nearly 61% of patients in Europe receive disease-modifying therapies through reimbursement-supported healthcare services. Around 45% of treatment centers have expanded rehabilitation support programs for long-term multiple sclerosis care. Increasing demand for oral medications and biologic therapies is supporting treatment adoption across several countries. More than 40% of healthcare institutions are investing in digital monitoring solutions for neurological disorders. Rising awareness campaigns and early diagnosis initiatives are also helping improve patient treatment rates in the region.

Europe Market Size accounted for USD 1.80 Billion in 2026 with around 30% market share supported by strong clinical research activities, government healthcare support, and increasing use of advanced neurological therapies.

Asia-Pacific

Asia-Pacific is witnessing rapid growth in the Relapsing-Remitting Multiple Sclerosis (MS) Market due to improving healthcare infrastructure and rising awareness regarding neurological diseases. More than 43% of urban healthcare centers have increased neurological screening programs to support early diagnosis. Around 39% of patients are adopting advanced oral therapies because of better convenience and reduced hospital visits. Government healthcare investments and expansion of specialty neurology clinics are helping improve treatment accessibility. Nearly 34% of pharmaceutical companies are increasing distribution networks across Asia-Pacific countries to support growing treatment demand. Telemedicine adoption has also increased significantly for neurological consultations and patient follow-up services.

Asia-Pacific Market Size reached USD 1.32 Billion in 2026, representing approximately 22% market share due to rising patient awareness, expanding healthcare investments, and increasing availability of neurological treatment facilities.

Middle East & Africa

Middle East & Africa is gradually expanding in the Relapsing-Remitting Multiple Sclerosis (MS) Market because of improving healthcare infrastructure and growing focus on neurological treatment access. Nearly 31% of healthcare providers in urban areas are increasing investments in specialty neurology services and diagnostic technologies. Around 27% of patients are gaining access to disease-modifying therapies through expanding healthcare insurance programs. More than 24% of hospitals are improving neurological rehabilitation support for long-term patient management. Government healthcare awareness programs are helping increase early diagnosis rates across several countries. The adoption of telemedicine and remote consultation services has also increased by approximately 20%, helping improve patient follow-up care and treatment support in underserved regions.

Middle East & Africa Market Size stood at USD 0.53 Billion in 2026 with nearly 9% market share driven by improving healthcare access, rising neurological awareness, and expansion of specialty treatment facilities.

List of Key Relapsing-Remitting Multiple Sclerosis (MS) Market Companies Profiled

Investment Analysis and Opportunities in Relapsing-Remitting Multiple Sclerosis (MS) Market

The Relapsing-Remitting Multiple Sclerosis (MS) Market is attracting strong investments because of increasing neurological disorder cases and growing demand for advanced therapies. More than 52% of pharmaceutical companies are expanding research activities focused on immune-targeted treatment solutions. Around 48% of healthcare investors are supporting biologic therapy development because of rising patient preference for effective long-term care. Nearly 41% of neurology centers are increasing spending on advanced MRI imaging and digital monitoring technologies. Clinical trial activities related to relapsing-remitting multiple sclerosis therapies have increased by over 37%, helping improve treatment innovation and patient care quality. Around 34% of healthcare startups are focusing on telemedicine and digital health platforms for neurological disease management. Investment in personalized medicine and rehabilitation services is also rising steadily because more than 46% of patients require long-term symptom monitoring and therapy support. The increasing adoption of oral therapies and home-based healthcare solutions is creating additional opportunities for pharmaceutical manufacturers and healthcare providers worldwide.

New Products Development

New product development activities in the Relapsing-Remitting Multiple Sclerosis (MS) Market are increasing rapidly because healthcare companies are focusing on advanced neurological treatment options. More than 44% of pharmaceutical manufacturers are developing biologic therapies with improved relapse control performance. Around 39% of newly introduced therapies are focused on reducing immune system attacks and nerve inflammation. Oral medication development has increased by approximately 36% because patients prefer convenient treatment options with fewer hospital visits. Nearly 32% of companies are investing in combination therapies to improve patient response rates and symptom management. Digital treatment support applications and remote monitoring platforms have also expanded by over 28% to improve therapy adherence and patient engagement. The use of artificial intelligence in neurological diagnosis and drug development is growing steadily across research organizations. Companies are also focusing on reducing side effects and improving long-term patient mobility through advanced drug formulations and targeted treatment technologies.

Developments

• Biogen: Expanded its neurological therapy support programs by improving patient monitoring services and increasing treatment access across multiple healthcare institutions. The company reported over 30% improvement in patient therapy engagement and expanded digital healthcare support activities for relapsing-remitting multiple sclerosis management.
• Novartis AG: Increased production capabilities for advanced biologic therapies and strengthened neurological research programs. More than 26% of its new research focus was directed toward immune-targeted therapies aimed at reducing relapse frequency and improving patient mobility conditions.
• Merck KGaA: Enhanced its oral therapy portfolio for relapsing-remitting multiple sclerosis patients and expanded treatment awareness programs. The company observed approximately 22% higher patient participation in long-term neurological treatment support initiatives.
• Sanofi Genzyme: Improved clinical collaboration activities with neurology centers and expanded rehabilitation support programs for multiple sclerosis patients. Around 25% increase in treatment accessibility initiatives was recorded across selected healthcare networks and specialty care institutions.
• Teva Pharmaceutical Industries Ltd: Strengthened research activities related to neurological disease therapies and increased focus on patient-centered treatment solutions. More than 20% growth in digital treatment management services supported better patient follow-up and therapy adherence programs.

Report Coverage

The report coverage of the Relapsing-Remitting Multiple Sclerosis (MS) Market provides detailed analysis of treatment trends, market segmentation, competitive landscape, regional outlook, and future growth opportunities. The study highlights increasing demand for disease-modifying therapies, biologics, oral medications, and rehabilitation services across global healthcare systems. More than 64% of patients prefer long-term treatment solutions that help reduce relapse frequency and improve mobility conditions. SWOT analysis within the report identifies strong growth opportunities through personalized medicine, digital monitoring platforms, and biologic therapy innovation. Around 48% of healthcare institutions are expanding investments in advanced neurological diagnosis technologies and telemedicine services.

The competitive analysis section evaluates strategies used by major pharmaceutical companies including biologic therapy expansion, digital healthcare integration, and clinical research investments. More than 44% of manufacturers are focusing on advanced immune-targeted treatment development to improve long-term patient outcomes. The report further explains patient behavior patterns, therapy adoption rates, outpatient treatment trends, and rehabilitation demand across different healthcare settings. Growing awareness regarding early diagnosis and personalized treatment plans is expected to support long-term market expansion globally.

Future Scope

The future scope of the Relapsing-Remitting Multiple Sclerosis (MS) Market looks strong because of continuous advancements in neurological therapies, personalized medicine, and digital healthcare solutions. More than 58% of healthcare providers are expected to increase the use of targeted biologic therapies to improve relapse control and reduce disease progression risks. Around 47% of pharmaceutical companies are focusing on advanced oral therapies and immune-based treatment technologies to improve patient comfort and therapy effectiveness. The use of artificial intelligence and digital monitoring systems is projected to increase significantly for early diagnosis and long-term patient management.

Emerging economies are projected to create additional growth opportunities due to improving healthcare infrastructure and rising awareness regarding neurological disorders. Nearly 36% of healthcare investments in developing regions are being directed toward specialty neurological care and digital treatment platforms. Pharmaceutical manufacturers are also increasing research activities related to combination therapies, biologics, and neuroprotective treatments to improve long-term patient outcomes. The integration of advanced analytics, wearable health devices, and digital support programs is expected to improve therapy adherence and patient engagement globally. Increasing collaboration between pharmaceutical companies, research organizations, and healthcare providers will continue supporting innovation and treatment accessibility in the Relapsing-Remitting Multiple Sclerosis (MS) Market.

Relapsing-Remitting Multiple Sclerosis (MS) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5.57 Billion in 2026
Market Size Value By	USD 11.45 Billion by 2035
Growth Rate	CAGR of 7.47% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Immunomodulating Drugs Nrf2 Activators Interferons Others By Application : Hospitals Clinics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Frequently Asked Questions

• What value is the Relapsing-Remitting Multiple Sclerosis (MS) Market expected to touch by 2035?

  The global Relapsing-Remitting Multiple Sclerosis (MS) Market is expected to reach USD 11.45 Billion by 2035.

• What CAGR is the Relapsing-Remitting Multiple Sclerosis (MS) Market expected to exhibit by 2035?

  The Relapsing-Remitting Multiple Sclerosis (MS) Market is expected to exhibit a CAGR of 7.47% by 2035.

• Who are the top players in the Relapsing-Remitting Multiple Sclerosis (MS) Market?

  Glenmark Pharmaceuticals, Eisai Co., Ltd, Biogen, Merck KGaA, Sanofi Genzyme, Novartis AG, Teva Pharmaceutical Industries Ltd,

• What was the value of the Relapsing-Remitting Multiple Sclerosis (MS) Market in 2025?

  In 2025, the Relapsing-Remitting Multiple Sclerosis (MS) Market value stood at USD 5.57 Billion.

Related Reports

Hydronephrosis Market Industrial Vacuum Evaporation Systems Market Hardware Acceleration Market Aortic Coarctation Market Virtual Reality, Augmented Reality & Mixed Reality Market Iron & Steel Scrap Recycling Market